... Skip to content
World IP Day 2026 — Recognized Innovator

Cynthia Bamdad

  • CEO
  • Minerva Biotechnologies Corporation

Recognized for scientific and executive leadership at Minerva Biotechnologies, where her work connects cancer immunotherapy, stem cell biology, and MUC1*-targeted therapeutics.

She then helped shape a patent portfolio around the mechanisms that regulate both cancer and stem cell growth.

Certificate of Recognition

Top IP Innovator — Cancer Immunotherapy & Stem Cell Biology · 2026

Minerva Patents (last 5 years)
0 +
First Filing
2009
USPTO Art Unit Focus
1642 / 1643
Role
CEO
Presented by InspireIP

World IP Day Recognition Series · 2026

Minerva Biotechnologies patents, last 5 years
0 +
Filed in 2025 alone
0
Recognition category
0 Biotech & Organic
The Recognition

From Harvard discovery to the most important cancer drug targets

Section eyebrow: The Recognition Section title: From Harvard discovery to the most important cancer drug targets

On World IP Day 2026, InspireIP recognizes Cynthia Bamdad, CEO of Minerva Biotechnologies, for her scientific leadership in cancer immunotherapy and stem cell biology.

The recognition is based on Minerva’s patent activity and Cynthia’s role in shaping the company’s core scientific direction.

Minerva’s work centers on MUC1* biology and the mechanisms that regulate cancer cell growth and early stem cell growth. The company’s patent portfolio protects methods for targeting these pathways in cancer therapeutics and regenerative medicine.

Cynthia earned her PhD in Biophysics from Harvard University and later founded Minerva Biotechnologies in 2009. Under her leadership, the company has advanced programs across MUC1*-targeted CAR T therapy, antibody-drug conjugates, stem cell growth regulation, and AlphaSTEM® technology.

Minerva’s lead work includes therapeutic approaches directed at MUC1*-positive solid tumors, a target the company connects to a large share of cancers.

MUC1* Cancer Targeting
CAR T Immunotherapy
Antibody-Drug Conjugates
Stem Cell Growth Regulation
Cancer-Stem Cell Biology
Solid Tumor Therapeutics
Patent Footprint

A portfolio shaped around the two molecules that control cancer and stem cell growth

1999–2014

Cynthia Bamdad founds Minerva Biotechnologies in Waltham, Massachusetts. The company begins building its patent position around cancer biology, stem cell growth, and MUC1*-targeted therapeutic approaches.

2015–2019

Minerva expands its portfolio across cancer immunotherapy and regenerative medicine. The company continues developing its work around MUC1*, stem cell growth regulation, and therapeutic targeting.

2020–2022

Patent activity accelerates, with 17 filings in 2020. Minerva advances its MUC1*-CAR T program and continues building protection around cancer and stem cell technologies.

2023–2025

The portfolio expands further into MUC1*-targeted therapeutics, antibody-drug conjugate work, and regenerative medicine applications. Minerva also reports progress in patient-derived stem cells for therapeutic regenerative medicine.

Cancer Immunotherapy & Stem Cell Biology

A small-entity company with breakthrough science

Minerva Biotechnologies is classified by the USPTO as a Small Entity, yet its five-year patent activity reflects a company with some of the most fundamental discoveries in cancer and stem cell biology. 

The portfolio is concentrated in the biotech and organic chemistry art units that protect cancer immunotherapy methods, stem cell growth regulation, therapeutic antibodies, and cell-based therapeutics.

Patents, last 5 years
Peak year (2020)
Filings
USPTO entity status
Small Entity
Art unit focus
1642 / 1643
"Leading an innovation program is harder than inventing on your own. It means choosing what to file, who to credit, and where to invest, over and over, for years. The leaders we recognize on World IP Day have done that consistently, and built something that compounds."

Sam Zellner

Founder, InspireIP · Inventor · Innovation Leader

About Minerva Biotechnologies Corporation

Built in Waltham, targeting the two molecules behind 75% of solid tumors

Founded in 1999 and headquartered in Waltham, Massachusetts, Minerva Biotechnologies develops cancer immunotherapies and regenerative medicine technologies.

The company’s cancer program focuses on MUC1*, a therapeutic target associated with many solid tumors. Its work includes MUC1*-targeted CAR T therapy and antibody-drug conjugate programs.

Minerva also develops stem cell technologies through its regenerative medicine work and AlphaSTEM® platform.

The company’s patent activity supports both sides of its scientific focus: turning growth pathways off in cancer and using related biology to support stem cell growth.

IP Day 2027

Know an IP innovator who deserves recognition?

Each year we recognize the inventors and IP leaders behind the portfolios that protect what their companies create. That includes founder-inventors whose contributions often go unmarked. Nominate someone for next year’s list.

Subscribe to Trust Center Updates

Subscribe to get notifications about important update to InspireIP's compliance journey.
By signing up for email notifications you agree to the privacy policy.

InspireIP has restricted access for 'System Acquisition and Development Lifecycle Policy'. We need your work email to validate OR request your access to this item.